Qatanani Mo

Chief Scientific Officer Qatanani Mo sold 136.5K shares of SRRK at $45.21 for $6.2M, reducing stake by 55.6%.

Qatanani Mo, Chief Scientific Officer of Scholar Rock, executed a substantial reduction of his SRRK stake, selling 136,462 shares at $45.21 on 2025-12-04 for $6,169,788.18. His post-transaction holdings of 108,964 shares represent a 55.6% reduction from his pre-transaction position of 245,426 shares. This sale arrives within a strong price momentum window—the stock is up 60.8% over the past 30 days and 43.3% over 90 days, trading at $45.02 (3.7% below the 52-week high of $46.73). Notably, across his prior four trades at SRRK, each subsequent measurement showed negative 90-day returns (ranging from -8.7% to -15.2%), with all four prior trades proving well-timed; his cross-ticker track record also exhibits a 100.00% well-timed rate on sells. The company remains unprofitable (full-year net income was negative, latest quarterly net income was $-102.2M) despite strong revenue growth of 76.4% annually, a context in which a senior executive's large discretionary sale may signal heightened valuation concerns relative to near-term fundamentals.

Scholar Rock Chief Scientific Officer sells 72,645 shares for $2.7M over two days; 39.5% of holdings liquidated at blended $37.37 avg

Qatanani Mo executed 4 separate sales totaling 72,645 shares for $2,714,767.41 across February 18–19, reducing his stake from 183,729 to 111,084 shares. The blended average price of $37.37 sits modestly below the current price of $39.15 but well above the 52-week low of $7.07, reflecting a volatile recovery phase for the stock (+30.8% over 90 days). Scholar Rock remains unprofitable (full-year net income was negative, latest quarter showed net loss of $-64,479,000.00) despite strong revenue growth of +76.4% year-over-year, indicating the company is in an investment phase typical of biotech firms. The 39.5% reduction in holdings by a Chief Scientific Officer at a loss-making firm during a period of significant stock volatility warrants investor attention to the company's cash burn trajectory and development timeline.